ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Decision on EU marketing authorisation for this population expected by September 2024
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Subscribe To Our Newsletter & Stay Updated